| ²é¿´: 354 | »Ø¸´: 3 | ||
| ¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û2´Î£¬×÷ÕßhuigenghaoÔö¼Ó½ð±Ò 1 ¸ö | ||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | ||
huigenghaoÖÁ×ðľ³æ (ÖøÃûдÊÖ)
|
[×ÊÔ´]
Quality Systems and Risk Management Approaches for Networked Drug Development
|
|
|
Quality Systems and Risk Management Approaches for Networked Drug Development David A. Moyer VP, Regulatory Compliance Programs Fulcrum Pharma Developments, Inc. PDA SciTech Summit Orlando, Florida March 10, 2004 |
» ²ÂÄãϲ»¶
ÀöˮѧԺ²ÄÁÏÓëÄÜÔ´¹¤³ÌѧԺÕÐÊÕµ÷¼Á£¡£¨¿Éµ÷¼Áרҵ·¶Î§¹ã£©
ÒѾÓÐ0È˻ظ´
Çç´¨ÍòÀïÐÂÊé
ÒѾÓÐ4È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ229È˻ظ´
ÔÚÏßÇóÖú£¬¼±£¡£¡£¡ÇëÎÊÄÄÀï¿ÉÒÔ×ö´ÅÐÔÄÉÃײÄÁϵĸ߷ֱæÍ¸Éäµç¾µµÄ²âÊÔ±íÕ÷ѽ£¿
ÒѾÓÐ5È˻ظ´
ʹÓÃMolAICalÉú³ÉС·Ö×ÓCHARMMÁ¦³¡ÍØÆËºÍ²ÎÊýÎļþ
ÒѾÓÐ0È˻ظ´
¸£ÖÝ´óѧÀîÐËÊç½ÌÊÚ¿ÎÌâ×é¼±Õв©Ê¿Ñо¿Éú
ÒѾÓÐ9È˻ظ´
Liquid Chromatography-Mass Spectrometry Analysis of Small Interfering RNAs
ÒѾÓÐ1È˻ظ´
Õâ¸ö×Ô·¢¼ÓÑõ·´Ó¦µÄ»úÀíÊÇʲô£¿
ÒѾÓÐ7È˻ظ´
¼Ó°ÍÅç¶¡½ºÄÒ¼¤ËØ6Ô³¬ÏÞÔÓÖʽṹ
ÒѾÓÐ4È˻ظ´
ÖÐÒ©¼ì²âÖÖ¾öÃ÷×Ó¡¢è×ʵ¡¢Ë®òΡ¢ÜòÜ߯·ÖÖ¼ì²âÎÊÌâ½»Á÷
ÒѾÓÐ1È˻ظ´
2Â¥2007-10-09 10:56:31









»Ø¸´´ËÂ¥
30